Interestingly, IRF4 mutations replacing lysine (K) residues, which serve as potential acetylation sites, have been reported in approximately 3% to 4% of patients with newly diagnosed MM (25, 31, 32). This evidence concerns the gene IRF4 and Miyoshi myopathy.